Medtronic plc (MDT) Net Income CAGR:10.05%(TTM)
The net income cagr for Medtronic plc (MDT) is +10.05% over the latest trailing 12-month period. Net income CAGR uses precomputed financial statement history.
The net income cagr for Medtronic plc (MDT) stock is 10.05% over the past 12 months. The 3 year average growth rate is 5.28% and the 5 year cagr is 10.17%. Net income CAGR shows how Medtronic plc's bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
MDT Net Income CAGR Chart
Medtronic plc (MDT)
MDT Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | $4.66B | $4.80B | +$138.00M | +2.96% | +2.96% |
| 2025 | $3.68B | $4.66B | +$986.00M | +26.82% | +26.82% |
| 2024 | $3.76B | $3.68B | $-82.00M | -2.18% | -2.18% |
| 2023 | $5.04B | $3.76B | $-1.28B | -25.42% | -25.42% |
| 2022 | $3.61B | $5.04B | +$1.43B | +39.74% | +39.74% |
| 2021 | $4.79B | $3.61B | $-1.18B | -24.70% | -24.70% |
| 2020 | $4.63B | $4.79B | +$158.00M | +3.41% | +3.41% |
| 2019 | $3.10B | $4.63B | +$1.53B | +49.19% | +49.19% |
| 2018 | $4.03B | $3.10B | $-924.00M | -22.94% | -22.94% |
| 2017 | $3.54B | $4.03B | +$490.00M | +13.85% | +13.85% |
| 2016 | $2.67B | $3.54B | +$863.00M | +32.26% | +32.26% |
| 2015 | $3.06B | $2.67B | $-390.00M | -12.72% | -12.72% |
| 2014 | $3.47B | $3.06B | $-402.00M | -11.60% | -11.60% |
| 2013 | $3.62B | $3.47B | $-150.00M | -4.15% | -4.15% |
| 2012 | $3.10B | $3.62B | +$521.00M | +16.83% | +16.83% |
| 2011 | $3.10B | $3.10B | $-3.00M | -0.10% | -0.10% |
| 2010 | $2.17B | $3.10B | +$930.00M | +42.88% | +42.88% |
| 2009 | $2.23B | $2.17B | $-62.00M | -2.78% | -2.78% |
| 2008 | $2.80B | $2.23B | $-571.00M | -20.38% | -20.38% |
| 2007 | $2.55B | $2.80B | +$255.30M | +10.02% | +10.02% |
| 2006 | $1.80B | $2.55B | +$742.80M | +41.18% | +41.18% |
| 2005 | $1.96B | $1.80B | $-155.40M | -7.93% | -7.93% |
| 2004 | $1.60B | $1.96B | +$359.50M | +22.47% | +22.47% |
| 2003 | $984.00M | $1.60B | +$615.80M | +62.58% | +62.58% |
| 2002 | $1.05B | $984.00M | $-62.00M | -5.93% | -5.93% |
| 2001 | $1.10B | $1.05B | $-52.50M | -4.78% | -4.78% |
| 2000 | $468.40M | $1.10B | +$630.10M | +134.52% | +134.52% |
| 1999 | $594.60M | $468.40M | $-126.20M | -21.22% | -21.22% |
| 1998 | $583.20M | $594.60M | +$11.40M | +1.95% | +1.95% |
Quarterly Net Income — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q4 2026 | $1.24B | +8.7% | +17.6% |
| Q3 2026 | $1.14B | -16.8% | -11.7% |
| Q2 2025 | $1.37B | +32.1% | +8.2% |
| Q1 2025 | $1.04B | -1.6% | -0.2% |
| Q4 2025 | $1.06B | -18.3% | +61.6% |
| Q3 2025 | $1.29B | +1.9% | -2.1% |
| Q2 2024 | $1.27B | +21.9% | +39.7% |
| Q1 2024 | $1.04B | +59.3% | +31.7% |
| Q4 2024 | $654.00M | -50.5% | -44.5% |
| Q3 2024 | $1.32B | +45.4% | +8.2% |
| Q2 2023 | $909.00M | +14.9% | +112.9% |
| Q1 2023 | $791.00M | -32.9% | -14.9% |
| Q4 2023 | $1.18B | -3.5% | -20.6% |
| Q3 2023 | $1.22B | +186.2% | -17.4% |
| Q2 2022 | $427.00M | -54.0% | -67.4% |
| Q1 2022 | $929.00M | -37.4% | +21.8% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha